Cargando…
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is 1 of the leading causes of infant mortality. SMA is mostly caused by low levels of Survival Motor Neuron (SMN) protein due to deletion of or mutation in the SMN1 gene. Its nearly identical copy, SMN2, fails to compensate for the loss of SMN1 due to predominant skippi...
Autores principales: | Singh, Ravindra N, Ottesen, Eric W, Singh, Natalia N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691903/ https://www.ncbi.nlm.nih.gov/pubmed/33283185 http://dx.doi.org/10.1177/2633105520973985 |
Ejemplares similares
-
Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
por: Ottesen, Eric W, et al.
Publicado: (2023) -
Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene
por: Seo, Joonbae, et al.
Publicado: (2016) -
Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy
por: Ottesen, Eric W., et al.
Publicado: (2016) -
An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy
por: Singh, Natalia N., et al.
Publicado: (2013) -
Activation of a cryptic 5′ splice site reverses the impact of pathogenic splice site mutations in the spinal muscular atrophy gene
por: Singh, Natalia N., et al.
Publicado: (2017)